|Auxilium Pharmaceuticals Inc.|
640 Lee Road
United States - Map
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, focuses on developing and marketing pharmaceutical products in urology and sexual health worldwide. The company markets Testim for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a non-oral drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; Striant, a buccal delivery system for testosterone replacement therapy; and XIAFLEX for the treatment of adult Dupuytrens contracture patients with a palpable cord. It also markets Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. In addition, the company is developing XIAFLEX, which is in Phase III clinical trial for the treatment of Peyronies disease; and in Phase II clinical trial for the treatment of adhesive capsulitis, as well as in Phase II clinical trial for the treatment of edematous fibrosclerotic panniculopathy. Further, it is developing a high concentration testosterone gel product. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. It has collaboration with the Swedish Orphan Biovitrum AB for the development, supply, and commercialization of XIAPEX. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.
|Auxilium Pharmaceuticals Inc.’s ISS Governance QuickScore as of Dec 1, 2013 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Adrian Adams ,
Chief Exec. Officer, Pres and Director
|Mr. James E. Fickenscher ,
Chief Financial Officer and Principal Accounting Officer
|Mr. Andrew I. Koven ,
Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec.
|Mr. Alan J. Wills ,
Exec. VP of Corp. Devel.
|Dr. James Patrick Tursi M.D.,
Chief Medical Officer
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|